IO

Inning One Ventures

North America, New York, United States, New York

Description

Inning One Ventures is an early-stage life science venture capital firm.

Investor Profile

Inning One Ventures has made 2 investments, with 1 in the past 12 months and 0% as lead.

Stage Focus

  • Series C (50%)
  • Series Unknown (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Life Science
  • Medical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Inning One Ventures frequently co-invest with?

Eli Lilly & Company Foundation
North America, Indiana, United States, Indianapolis
Co-Investments: 1
EcoR1 Capital
North America, California, United States, San Francisco
Co-Investments: 2
Goldman Sachs Asset Management
North America, New York, United States, New York
Co-Investments: 1
Schrödinger
North America, New York, United States, New York
Co-Investments: 2
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 1
NYU Langone Health
North America, New York, United States, New York
Co-Investments: 1
Point72 Ventures
North America, New York, United States, New York
Co-Investments: 1
Memorial Sloan - Kettering Cancer Center
North America, New York, United States, New York
Co-Investments: 1
Vivo Capital
North America, California, United States, Palo Alto
Co-Investments: 1
Boxer Capital
North America, Florida, United States, Windermere
Co-Investments: 2

What are some of recent deals done by Inning One Ventures?

Ajax Therapeutics

Cambridge, Massachusetts, United States

Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.

BiotechnologyLife ScienceMedical
Series CMay 13, 2024
Amount Raised: $95,000,000
Ajax Therapeutics

Cambridge, Massachusetts, United States

Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.

BiotechnologyLife ScienceMedical
Series UnknownJun 1, 2021
Amount Raised: $40,000,000